PACB
Pacific Biosciences of California Inc

14,461
Mkt Cap
$721.56M
Volume
3.72M
52W High
$2.73
52W Low
$0.8511
PE Ratio
-1.07
PACB Fundamentals
Price
$2.32
Prev Close
$2.39
Open
$2.36
50D MA
$1.75
Beta
2.16
Avg. Volume
10M
EPS (Annual)
-$1.59
P/B
19.40
Rev/Employee
$267,850.43
Loading...
Loading...
News
all
press releases
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 8.2% - Here's What Happened
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 8.2% - Time to Sell...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.
Zacks·3d ago
News Placeholder
Pacific Biosciences of California, Inc. $PACB Shares Sold by Edmond DE Rothschild Holding S.A.
Edmond DE Rothschild Holding S.A. decreased its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 38.8% during the 2nd quarter, according to the company in...
MarketBeat·3d ago
News Placeholder
Pacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week High - What's Next?
Pacific Biosciences of California (NASDAQ:PACB) Sets New 1-Year High - Here's Why...
MarketBeat·3d ago
News Placeholder
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 7% - Still a Buy?
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 7% - Should You Buy...
MarketBeat·9d ago
News Placeholder
Pacific Biosciences of California (NASDAQ:PACB) Shares Cross Above 200 Day Moving Average - Here's Why
Pacific Biosciences of California (NASDAQ:PACB) Stock Crosses Above 200 Day Moving Average - Should You Sell...
MarketBeat·10d ago
News Placeholder
Top 3 Genomics Stocks to Consider for Your Portfolio
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Zacks·11d ago
News Placeholder
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·16d ago
News Placeholder
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Expected to Rise, Piper Sandler Analyst Says
Piper Sandler boosted their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a "neutral" rating in a report on Tuesday...
MarketBeat·17d ago
News Placeholder
Stephens Issues Positive Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price
Stephens increased their price objective on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an "overweight" rating in a report on Monday...
MarketBeat·18d ago

Latest PACB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.